CBIO- Crescent Biopharma, Inc.

Insider activity in CBIO over the last quarter tilts toward selling: insiders offloaded a net 16,726 shares worth roughly $286K.

Classified under Biotechnology (Health Care sector), CBIO's insider flows are most useful compared with peers in the same group.

Insider Ownership

Role	Insider	Shares	Value	30d
10%	Fairmount Funds Management LLC	3.60M	$52.22M	-
CEO	Brumm Joshua T	271.8K	$4.54M	-
COO	McNeill Jonathan	134.6K	$2.25M	-
Other	Doughty Christopher Grant	54.2K	-	-
Other	Pinkas Jan	21.6K	$386.3K	-

Buys and sells only

10 filings

Date	Insider	Role	Type	Shares	Price	Value	Chg%	3M	12M
Sep 18, 2026	Brumm Joshua T54	Chief Executive Officer	Sell	9,447	$16.91	$159,775.27	-3.4%	-	-
Sep 18, 2026	McNeill Jonathan55	President And COO	Sell	4,570	$16.90	$77,234.59	-3.3%	-	-
Sep 16, 2026	Scalzo Richard William58	Chief Financial Officer	Sell	568	$17.90	$10,167.20	-2.8%	-	-
Sep 16, 2026	Bispham Barbara Harlin	See Remarks	Sell	620	$17.90	$11,098.00	-3.2%	-	-
Sep 16, 2026	Im Ellie Eunkyung	Chief Medical Officer	Sell	623	$17.90	$11,151.70	-2.8%	-	-
Sep 16, 2026	Pinkas Jan	Chief Scientific Officer	Sell	658	$17.90	$11,778.20	-3.0%	-	-
Sep 16, 2026	Lynch Ryan	See Remarks	Sell	240	$17.90	$4,296.00	-1.7%	-	-
Jul 16, 2026	Fairmount Funds Management LLC74	Director, 10% Owner	Buy	853,450	$14.50	$12,375,025.00	+31.1%	-16.7%	-
Jun 22, 2026	Brumm Joshua T54	Chief Executive Officer	Sell	42,305	$17.99	$761,066.95	-13.1%	-7.5%	-
Jun 22, 2026	Bispham Barbara Harlin	See Remarks	Sell	1,218	$17.99	$21,911.82	-5.9%	-7.5%	-